Company Profile
EUROIMMUN Medizinische Labordiagnostika AG is a Germany-based manufacturer of medical laboratory diagnostics, headquartered in Lübeck, Germany. Founded in September 1987 by Professor Winfried Stöcker as a spin-off from the University of Lübeck, the company operates as a core subsidiary of Revvity, Inc. (NYSE: RVTY) (formerly PerkinElmer Diagnostics), serving global clinical diagnostics markets in over 150 countries with approximately 3,500 employees.
Core Products ＆ Technologies
Autoimmune ＆ Allergy Diagnostics
• IIFT (Indirect Immunofluorescence Tests): BIOCHIP-based assays for detection of autoantibodies in autoimmune diseases such as rheumatoid arthritis, lupus, and vasculitis
• ELISA: Enzyme-linked immunosorbent assays featuring designer antigens for quantitative antibody detection
• EUROLINE Immunoblots: Line blot assays for multiplex antibody profiling in autoimmune and infectious disease diagnosis
• EUROArray Microarrays: Molecular genetic microarrays for identification of gene polymorphisms and pathogen detection
Infectious Disease ＆ Molecular Diagnostics
• ChLIA (Chemiluminescence Immunoassays): High-sensitivity quantitative assays for infectious disease serology and biomarker detection
• PCR-Based Assays: Molecular diagnostic kits for direct pathogen detection including Zika virus, pregnancy-relevant infections, and vaccine-preventable diseases
• EURORealTime: Real-time PCR systems for viral and bacterial load quantification
Automation ＆ Software
• EUROPattern Microscope Live: Fully automated immunofluorescence microscope with AI-powered pattern recognition and titer estimation, acquiring images in under two seconds
• IDS i20 Platform: CE-marked and FDA-listed fully automated chemiluminescence platform processing up to 140 tests per hour across endocrinology, allergy, autoimmune, infectious disease, Alzheimer’s, and TDM
• EUROLabOffice 4.0: Laboratory information and workflow management software for integrated diagnostics
Market Position ＆ Certifications
EUROIMMUN holds a global leadership position in the autoimmune and allergy in vitro diagnostics market, competing with Thermo Fisher Scientific (Phadia/ImmunoCAP) and Roche Diagnostics in the immunodiagnostics segment. Key strengths include:
• 39 years of German diagnostics heritage since founding
• BIOCHIP pioneer: Developed the first BIOCHIP in 1983; today uses fully automated in-house designed fragmentation and production machines worldwide
• Regulatory compliance: FDA-registered facility (EUROIMMUN US); ISO 13485:2016 certified; CE marked; compliant with EU IVDR
• Global reach: 15 international subsidiaries covering 35+ countries; cooperates with 60+ distributors; products used in 150+ countries
• Education infrastructure: Euroimmun Academy trains 1,000+ customers from 100+ countries annually; accredited Institute for Quality Assessment offers external quality assurance schemes
Corporate Timeline
1983 — Development of the first BIOCHIP technology at the University of Lübeck
1987 — Founded as EUROIMMUN Medizinische Labordiagnostika AG in Lübeck, Germany
2017 — Acquired by PerkinElmer, Inc. for approximately $1.3 billion
2021 — Immunodiagnostic Systems (IDS) joined the PerkinElmer family and began close cooperation with EUROIMMUN
2023 — Became part of Revvity, Inc. following the PerkinElmer divisional split
2025 — Launched IDS i20 fully automated chemiluminescence platform; IDS fully integrated into EUROIMMUN UK portfolio (January)
2026 — Revvity announced plan to divest China immunodiagnostics business (approximately 6% of 2025 revenue); EUROIMMUN China launched "Localization Strategy 2.0" to transition to local management-led independent operation (May); signed letter of intent with potential acquirer, formal agreement expected Q2 2026, transaction completion targeted for 2027
Target Markets ＆ Applications
• Autoimmune Disease: IIFT, ELISA, and immunoblot panels for rheumatoid arthritis, systemic lupus erythematosus, vasculitis, and autoimmune hepatitis
• Infectious Disease: Serological and molecular assays for Zika, Lyme disease, pregnancy-relevant infections, and vaccine-preventable diseases
• Allergy Diagnostics: Specific IgE detection for birch, Timothy grass pollen, and other inhalant and food allergens
• Genetic Analysis: EUROArray microarrays for pharmacogenomics and pathogen genotyping
• Laboratory Automation: EUROPattern and IDS i20 platforms for high-throughput automated immunodiagnostics in hospital and reference labs
Contact Information
Global Headquarters
Address: Seekamp 31, 23560 Lübeck, Germany
Telephone: +49 451 2032-0
Fax: +49 451 2032-100
Website: euroimmun.com
Parent Company
Revvity, Inc.
Address: Waltham, Massachusetts, USA
Stock: NYSE: RVTY
Website: revvity.com
Investor Relations: ir.revvity.com
